These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 32682371)

  • 1. Kratom Dependence and Treatment Options: A Comprehensive Review of the Literature.
    Bin Abdullah MFIL
    Curr Drug Targets; 2020; 21(15):1566-1579. PubMed ID: 32682371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users.
    Singh D; Müller CP; Vicknasingam BK
    Drug Alcohol Depend; 2014 Jun; 139():132-7. PubMed ID: 24698080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Pharmacology of the Dietary Supplement Kratom (Mitragyna speciosa).
    Hartley C; Bulloch M; Penzak SR
    J Clin Pharmacol; 2022 May; 62(5):577-593. PubMed ID: 34775626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Complex Case of Kratom Dependence, Depression, and Chronic Pain in Opioid Use Disorder: Effects of Buprenorphine in Clinical Management.
    Bowe A; Kerr PL
    J Psychoactive Drugs; 2020; 52(5):447-452. PubMed ID: 32546067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case report of inpatient detoxification after kratom (Mitragyna speciosa) dependence.
    McWhirter L; Morris S
    Eur Addict Res; 2010; 16(4):229-31. PubMed ID: 20798544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kratom policy: The challenge of balancing therapeutic potential with public safety.
    Prozialeck WC; Avery BA; Boyer EW; Grundmann O; Henningfield JE; Kruegel AC; McMahon LR; McCurdy CR; Swogger MT; Veltri CA; Singh D
    Int J Drug Policy; 2019 Aug; 70():70-77. PubMed ID: 31103778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kratom: Substance of Abuse or Therapeutic Plant?
    Gorelick DA
    Psychiatr Clin North Am; 2022 Sep; 45(3):415-430. PubMed ID: 36055730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kratom Alkaloids, Natural and Semi-Synthetic, Show Less Physical Dependence and Ameliorate Opioid Withdrawal.
    Wilson LL; Chakraborty S; Eans SO; Cirino TJ; Stacy HM; Simons CA; Uprety R; Majumdar S; McLaughlin JP
    Cell Mol Neurobiol; 2021 Jul; 41(5):1131-1143. PubMed ID: 33433723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the rewarding effects of mitragynine and 7-hydroxymitragynine in an intracranial self-stimulation procedure in male and female rats.
    Behnood-Rod A; Chellian R; Wilson R; Hiranita T; Sharma A; Leon F; McCurdy CR; McMahon LR; Bruijnzeel AW
    Drug Alcohol Depend; 2020 Oct; 215():108235. PubMed ID: 32889450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine.
    Hemby SE; McIntosh S; Leon F; Cutler SJ; McCurdy CR
    Addict Biol; 2019 Sep; 24(5):874-885. PubMed ID: 29949228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurobiology of Kratom and its main alkaloid mitragynine.
    Suhaimi FW; Yusoff NH; Hassan R; Mansor SM; Navaratnam V; Müller CP; Hassan Z
    Brain Res Bull; 2016 Sep; 126(Pt 1):29-40. PubMed ID: 27018165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severity of Pain and Sleep Problems during Kratom (Mitragyna speciosa Korth.) Cessation among Regular Kratom Users.
    Singh D; Narayanan S; Vicknasingam BK; Prozialeck WC; Ramanathan S; Zainal H; Harun SN
    J Psychoactive Drugs; 2018; 50(3):266-274. PubMed ID: 29558272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse.
    Warner ML; Kaufman NC; Grundmann O
    Int J Legal Med; 2016 Jan; 130(1):127-38. PubMed ID: 26511390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users.
    Singh D; Yeou Chear NJ; Narayanan S; Leon F; Sharma A; McCurdy CR; Avery BA; Balasingam V
    J Ethnopharmacol; 2020 Mar; 249():112462. PubMed ID: 31816368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severity of Kratom (Mitragyna speciosa Korth.) Psychological Withdrawal Symptoms.
    Singh D; Narayanan S; Müller CP; Swogger MT; Rahim AA; Leong Bin Abdullah MFI; Vicknasingam BK
    J Psychoactive Drugs; 2018; 50(5):445-450. PubMed ID: 30152738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of kratom dependence with buprenorphine/naloxone in a veteran population.
    Lei J; Butz A; Valentino N
    Subst Abus; 2021; 42(4):497-502. PubMed ID: 33617752
    [No Abstract]   [Full Text] [Related]  

  • 17. Changing trends in the use of kratom (Mitragyna speciosa) in Southeast Asia.
    Singh D; Narayanan S; Vicknasingam B; Corazza O; Santacroce R; Roman-Urrestarazu A
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28544011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mini review: Potential therapeutic values of mitragynine as an opioid substitution therapy.
    Harun N; Kamaruzaman NA; Mohamed Sofian Z; Hassan Z
    Neurosci Lett; 2022 Mar; 773():136500. PubMed ID: 35114335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-reported prevalence and severity of opioid and kratom (Mitragyna speciosa korth.) side effects.
    Saref A; Suraya S; Singh D; Grundmann O; Narayanan S; Swogger MT; Prozialeck WC; Boyer E; Chear NJY; Balasingam V
    J Ethnopharmacol; 2019 Jun; 238():111876. PubMed ID: 31014959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse.
    Kruegel AC; Grundmann O
    Neuropharmacology; 2018 May; 134(Pt A):108-120. PubMed ID: 28830758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.